The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
Open accessPublished version of a preprint
Abstract
BACKGROUND: Several cases of unusual thrombotic events and thrombocytopenia have developed after vaccination with the recombinant adenoviral vector encoding the spike protein antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (ChAdOx1 nCov-19, AstraZeneca). More data were needed on the pathogenesis of this unusual clotting disorder. METHODS: We assessed the clinical and laboratory features of 11 patients in Germany and Austria in whom thrombosis or thrombocytopenia had developed after vaccination with ChAdOx1 nCov-19. We used a standard enzyme-linked immunosorbent assay to detect platelet factor 4 (PF4)-heparin antibodies and a modified (PF4-enhanced) platelet-activation test to detect platelet-activating antibodies under various reaction conditions. Included in this testing were samples from patients who had blood samples referred for investigation of vaccine-associated thrombotic events, with 28 testing positive on a screening PF4-heparin immunoassay. RESULTS: Of the 11 original patients, 9 were women, with a median age of 36 years (range, 22 to 49). Beginning 5 to 16 days after vaccination, the patients presented with one or more thrombotic events, with the exception of 1 patient, who presented with fatal intracranial hemorrhage. Of the patients with one or more thrombotic events, 9 had cerebral venous thrombosis, 3 had splanchnic-vein thrombosis, 3 had pulmonary embolism, and 4 had other thromboses; of these patients, 6 died. Five patients had disseminated intravascular coagulation. None of the patients had received heparin before symptom onset. All 28 patients who tested positive for antibodies against PF4-heparin tested positive on the platelet-activation assay in the presence of PF4 independent of heparin. Platelet activation was inhibited by high levels of heparin, Fc receptor-blocking monoclonal antibody, and immune globulin (10 mg per milliliter). Additional studies with PF4 or PF4-heparin affinity purified antibodies in 2 patients confirmed PF4-dependent platelet activation. CONCLUSIONS: Vaccination with ChAdOx1 nCov-19 can result in the rare development of immune thrombotic thrombocytopenia mediated by platelet-activating antibodies against PF4, which clinically mimics autoimmune heparin-induced thrombocytopenia. (Funded by the German Research Foundation.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thrombocytopenia and immune thrombocytopenia (ITP) were also included due to their association with TTS and reports of ITP as an independent safety signal [7,19,20].”
From COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals (2024) · cites this paper as [19]
Experimental — accuracy not yet measuredIn the citing paper
“These adverse events, which primarily affect young women, have been linked with the ChAdOx1 nCoV-1932 and Ad26.COV2.S (Johnson & Johnson–Janssen) Covid-19 vaccines,33 both of which are adenoviral vector vaccines.”
From Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting (2021) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cuker, A. C., Arepally, G. M., Chong, B. H., Cines, D. B., Greinacher, A., Gruel, Y., Linkins, L. A., Rodner, S. B., Selleng, S., Warkentin, T. E., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018024489 · Cited by 755
Self-citationCLINICAL PRACTICE. Heparin-Induced Thrombocytopenia.
Greinacher, A. (2015) · PubMed · doi:10.1056/nejmcp1411910 · Cited by 612
Self-citationDelayed-Onset Heparin-Induced Thrombocytopenia and Thrombosis
Warkentin, T. E., & Kelton, J. G. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-7-200110020-00009 · Cited by 463
Self-citationAutoimmune heparin‐induced thrombocytopenia
Greinacher, A., Selleng, K., & Warkentin, T. E. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13813 · Cited by 414
Self-citationDelayed-Onset Heparin-Induced Thrombocytopenia
Rice, L., Attisha, W. K., Drexler, A. J., & Francis, J. L. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-3-200202050-00009 · Cited by 268
Othman, M., Labelle, A., Mazzetti, I., Elbatarny, H. S., & Lillicrap, D. (2006) · Blood · doi:10.1182/blood-2006-06-032524 · Cited by 220
Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review
Warkentin, T. E., Pai, M., & Linkins, L. (2017) · Blood · doi:10.1182/blood-2017-04-778993 · Cited by 210
Self-citationWarkentin, T. E. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1636645 · Cited by 180
Self-citationA Spontaneous Prothrombotic Disorder Resembling Heparin-induced Thrombocytopenia
Warkentin, T. E., Makris, M., Jay, R. M., & Kelton, J. G. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.03.012 · Cited by 170
Self-citationJuhl, D., Eichler, P., Lübenow, N., Strobel, U., Wessel, A., & Greinacher, A. (2006) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2005.00621.x · Cited by 170
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 1,001
Cutaneous small vessel vasculitis following single-dose Janssen Ad26.COV2.S vaccination
Berry, C. T., Eliliwi, M., Gallagher, S., Panaccione, S., Klein, W. M., Healy, A. L., Stoecker, B. A., & Kallas, R. (2021) · JAAD Case Reports · doi:10.1016/j.jdcr.2021.07.002 · Cited by 24
Kenda, J., Lovrič, D., Škerget, M., & Milivojević, N. (2021) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2021.106072 · Cited by 26
Global covid-19 vaccine rollout and safety surveillance—how to keep pace
Re, V. L., Klungel, O. H., Chan, K. A., Panozzo, C. A., Zhou, W., & Winterstein, A. G. (2021) · BMJ · doi:10.1136/bmj.n1416 · Cited by 26
Clark, R. T., Johnson, L., Billotti, J., Foulds, G., Ketels, T., Heard, K. J., & Hynes, E. C. (2021) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2021.04.035 · Cited by 27
Andraska, E., Kulkarni, R. N., Chaudhary, M. A., & Sachdev, U. (2021) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2021.07.009 · Cited by 26
Thromboembolism after COVID-19 vaccine in patients with preexisting thrombocytopenia
Mauriello, A., Scimeca, M., Amelio, I., Massoud, R., Novelli, A., Lorenzo, F. D., Finocchiaro, S., Cimino, C., Telesca, R., Chiocchi, M., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04058-z · Cited by 26
Datta, P., Zhang, F., Dordick, J. S., & Linhardt, R. J. (2021) · Thrombosis Journal · doi:10.1186/s12959-021-00318-2 · Cited by 26
COVID-19 associated coagulopathy: Mechanisms and host-directed treatment
Plášek, J., Gumulec, J., Máca, J., Škarda, J., Procházka, V., Grézl, T., & Václavík, J. (2021) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2021.10.012 · Cited by 29
Sacconi, R., Simona, F., Forte, P., & Querques, G. (2021) · Ophthalmology and Therapy · doi:10.1007/s40123-021-00441-3 · Cited by 26
Four cases of acquired hemophilia A following immunization with mRNA BNT162b2 SARS-CoV-2 vaccine
Leone, M. C., Canovi, S., Pilia, A., Casali, A., Depietri, L., Fasano, T., Colla, R., & Ghirarduzzi, A. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.01.017 · Cited by 26
Sheng, W., Chang, S., Lin, P., Hsieh, M., Chang, H., Cheng, C., Yang, H., Pan, C., Ieong, S., Chao, T., et al. (2022) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2022.02.020 · Cited by 26
Gattinger, P., Kratzer, B., Tulaeva, I., Niespodziana, K., Ohradanova‐Repic, A., Gebetsberger, L., Borochova, K., Garner‐Spitzer, E., Trapin, D., Höfer, G., et al. (2022) · Allergy · doi:10.1111/all.15305 · Cited by 26
Manifestation of Herpetic Eye Disease after COVID-19 Vaccine: A UK Case Series
Rallis, K. I., Fausto, R., Ting, D. S. J., Al-Aqaba, M. A., Said, D. G., & Dua, H. S. (2022) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2022.2046795 · Cited by 26
COVID‐19 disease and vaccination in pregnant and lactating women
Sáfadi, M. A. P., Spinardi, J., Swerdlow, D. L., & Srivastava, A. K. (2022) · American Journal of Reproductive Immunology · doi:10.1111/aji.13550 · Cited by 26
Jianu, D. C., Jianu, S. N., Dan, T. F., Munteanu, G., Copil, A., Bîrdac, C. D., Motoc, A. G. M., Axelerad, A. D., Petrică, L., Arnăutu, S.-F., et al. (2022) · Life · doi:10.3390/life12050717 · Cited by 26
Bae, S., Ko, J., Choi, J., Park, W., Lim, S. Y., Ahn, J. Y., Song, K.-H., Lee, K. H., Song, Y. G., Kim, Y. W., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.04.019 · Cited by 26
Immunogenicity and efficacy of Ad26. COV2 .S: An adenoviral vector–based COVID ‐19 vaccine
Gars, M. L., Hendriks, J., SADOFF, J. C., Ryser, M., Struyf, F., Douoguih, M., & Schuitemaker, H. (2022) · Immunological Reviews · doi:10.1111/imr.13088 · Cited by 30
Hajjo, R., Sabbah, D. A., & Tropsha, A. (2022) · Pathogens · doi:10.3390/pathogens11070743 · Cited by 28
Schönborn, L., Thiele, T., Esefeld, M., Debuch, K. E., Wesche, J., Seck, S. N., Kaderali, L., Wolff, M., Warkentin, T. E., & Greinacher, A. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15862 · Cited by 26
Self-citationFrom Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era
Miao, G., Chen, Z., Cao, H., Wu, W., Chu, X., Liu, H., Zhang, L., Zhu, H., Cai, H., Lu, X., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114208 · Cited by 27
Rescue Therapy in Chronic Prothrombotic Autoimmune Anti-PF4 Disorder
Lindhoff‐Last, E., Schönborn, L., Zaninetti, C., Warkentin, T. E., & Greinacher, A. (2023) · New England Journal of Medicine · doi:10.1056/nejmc2309016 · Cited by 26
Self-citationHow could a COVID vaccine cause blood clots? Scientists race to investigate
Ledford, H. K. (2021) · Nature · doi:10.1038/d41586-021-00940-0 · Cited by 26
Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis
Allen‐Philbey, K., Stennett, A., Begum, T., Johnson, A., Dobson, R., Giovannoni, G., Gnanapavan, S., Marta, M., Smets, I., Turner, B. P., et al. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103028 · Cited by 24
Venous Thromboembolism and Mild Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
Gabarin, N., Patterson, S. E., Pai, M., Afzaal, T., Nazy, I., Sheppard, J. I., Arnold, D. M., & Warkentin, T. E. (2021) · Thrombosis and Haemostasis · doi:10.1055/a-1585-6182 · Cited by 25
Self-citationChoi, J.-K., Kim, S., Kim, S., Jin, J., Choi, S. W., Kim, H., Yoo, J., Park, I. S., & Kim, S.-R. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e223 · Cited by 25
Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination
Gelbenegger, G., Cacioppo, F., Firbas, C., & Jilma, B. (2021) · Vaccines · doi:10.3390/vaccines9090956 · Cited by 25
Takotsubo (stress) cardiomyopathy after ChAdOx1 nCoV-19 vaccination
Crane, P., Wong, C. Y., Mehta, N., & Barlis, P. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-246580 · Cited by 25
Update on the COVID-19 Vaccine Research Trends: A Bibliometric Analysis
Xu, Z., Qu, H., Ren, Y., Gong, Z., Ri, H., Zhang, F., Chen, X., Zhu, W., Shao, S., & Chen, X. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s335745 · Cited by 25
Loo, L. K., Salim, O., Liang, D., Goel, A., Sumangala, S., Gowda, A. S., Davies, B., & Rajabally, Y. A. (2021) · Muscle & Nerve · doi:10.1002/mus.27461 · Cited by 25
Makris, M., & Pavord, S. R. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100274 · Cited by 25
mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2
Jin, Y., Hou, C., Li, Y., Zheng, K., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.821538 · Cited by 24
Longevity of vaccine protection: Immunological mechanism, assessment methods, and improving strategy
Chen, Z., Gao, X., & Yu, D. (2022) · Open Research (University of Surrey) · doi:10.1002/viw.20200103 · Cited by 30
Central nervous system adverse events after ChAdOx1 vaccination
Maramattom, B. V., Lotlikar, R. S., & Sukumaran, S. (2022) · Neurological Sciences · doi:10.1007/s10072-022-06000-3 · Cited by 25
Vaccine-induced immune thrombotic thrombocytopenia
Kanack, A. J., & Padmanabhan, A. (2022) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2022.101381 · Cited by 25
The first year of COVID-19 vaccine roll-out in Africa: challenges and lessons learned
Masresha, B., Ruiz, M. A. S., Atuhebwe, P. L., & Mihigo, R. (2022) · Pan African Medical Journal · doi:10.11604/pamj.supp.2022.41.2.33686 · Cited by 25
New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review
Alhumaid, S., Mutair, A. S. A., Rabaan, A. A., ALShakhs, F. M., Choudhary, O. P., Yong, S. J., Nainu, F., Khan, A., Muhammad, J., Alhelal, F., et al. (2022) · BMC Gastroenterology · doi:10.1186/s12876-022-02507-3 · Cited by 24
Seven classes of antiviral agents
Ianevski, A., Ahmad, S., Anunnitipat, K., Oksenych, V., Žusinaite, E., Tenson, T., Bjørås, M., & Kainov, D. E. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04635-1 · Cited by 27
Progress and challenges of mRNA vaccines
Lin, L., Pei, Y., Li, Z., & Luo, D. (2022) · Interdisciplinary medicine · doi:10.1002/inmd.20220008 · Cited by 26
New perspectives on the induction and acceleration of immune-associated thrombosis by PF4 and VWF
Liu, Z., Sun, M.-X., Hua, M.-Q., Zhang, H., Mu, G., Zhou, S. Y., Wang, Z., Xiang, Q., & Cui, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1098665 · Cited by 25
COVID-19 and Cardiovascular Diseases: From Cellular Mechanisms to Clinical Manifestations
Shu, H., Zheng, W., Li, N., Zhang, Z., Ceesay, B. M., Peng, Y., Zhou, N., & Wang, D. W. (2023) · Aging and Disease · doi:10.14336/ad.2023.0314 · Cited by 25
PRACTICAL RECOMMENDATIONS FOR THE MANAGEMENT OF PATIENTS WITH ITP DURING THE COVID-19 PANDEMIC
Rodeghiero, F. (2021) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2021.032 · Cited by 24
Post‐adenoviral‐based COVID‐19 vaccines thrombosis: A proposed mechanism
Kadkhoda, K. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15348 · Cited by 24
Jones, M., Boisvert, A., Landry, J., & Petrasek, P. F. (2021) · Canadian Medical Association Journal · doi:10.1503/cmaj.210795 · Cited by 24
Specker, C., Aries, P. M., Braun, J., Burmester, G. R., Fischer‐Betz, R., Hasseli, R., Holle, J. U., Hoyer, B. F., Iking‐Konert, C., Krause, A., et al. (2021) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-021-01055-7 · Cited by 24
Passariello, M., Vetrei, C., Amato, F., & Lorenzo, C. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168562 · Cited by 24
Syed, K. S., Chaudhary, H. A., & Donato, A. A. (2021) · American Journal of Case Reports · doi:10.12659/ajcr.933397 · Cited by 24
Rawahi, B. A., BaTaher, H., Jaffer, Z., Al‐Balushi, A., Al‐Mazrouqi, A., & Al‐Balushi, N. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12578 · Cited by 24
Innovative vaccine platforms against infectious diseases: Under the scope of the COVID-19 pandemic
Tsakiri, M., Naziris, N., & Demetzos, C. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121212 · Cited by 24
Rizzo, A. C., Giussani, G., & Agostoni, E. C. (2022) · Cerebrovascular Diseases · doi:10.1159/000524290 · Cited by 24
Thrombosis, cancer, and COVID-19
Brito-Dellan, N., Tsoukalas, N., & Font, C. (2022) · Supportive Care in Cancer · doi:10.1007/s00520-022-07098-z · Cited by 24
Orebi, H. A., Emara, H. E., Alhindi, A. A., Shahin, M. R., Hegazy, A. H., Kabbash, I., & Saied, S. M. (2022) · Tropical Medicine and Health · doi:10.1186/s41182-022-00427-2 · Cited by 27
Gianni, P., Goldin, M., Ngu, S., Zafeiropoulos, S., Geropoulos, G., & Giannis, D. (2022) · World Journal of Experimental Medicine · doi:10.5493/wjem.v12.i4.53 · Cited by 26
Piché‐Renaud, P., Morris, S. K., & Top, K. A. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15625 · Cited by 23
Gigante, B., Levy, J. H., Gorp, E. C. M. V., Bartoloni, A., Bochaton‐Piallat, M., Bäck, M., Cate, H. T., Christersson, C., Ferreiro, J. L., Geisler, T., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad388 · Cited by 27
Assessing a Rare and Serious Adverse Event Following Administration of the Ad26.COV2.S Vaccine
Karron, R. A., Key, N. S., & Sharfstein, J. M. (2021) · JAMA · doi:10.1001/jama.2021.7637 · Cited by 24
Parums, D. V. (2021) · Medical Science Monitor · doi:10.12659/msm.932899 · Cited by 24
Reid, J. A., & Mabhala, M. A. (2021) · Israel Journal of Health Policy Research · doi:10.1186/s13584-021-00470-0 · Cited by 24
Thrombotic thrombocytopenic purpura after ChAdOx1 nCoV-19 vaccine
Lee, H. P., Selvaratnam, V., & Rajasuriar, J. S. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-246049 · Cited by 23
Yoshida, K., Sakaki, A., Matsuyama, Y., Mushino, T., Matsumoto, M., Sonoki, T., & Tamura, S. (2021) · Internal Medicine · doi:10.2169/internalmedicine.8568-21 · Cited by 23
Adenoviral Inciting Antigen and Somatic Hypermutation in VITT
Wang, J. J., Schönborn, L., Warkentin, T. E., Müller, L., Thiele, T., Ulm, L., Völker, U., Ameling, S., Franzenburg, S., Kaderali, L., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2514824 · Cited by 23
Self-citationGeorge, G., Friedman, K. D., Curtis, B. R., & Lind, S. E. (2021) · American Journal of Hematology · doi:10.1002/ajh.26237 · Cited by 23
COVID-19 Vaccine Acceptance in Azuay Province, Ecuador: A Cross-Sectional Online Survey
Monge, J. C. J., Obimpeh, M., Vega, B., Páez, F. D. A., Boven, A., Verhoeven, V., & Colebunders, R. (2021) · Vaccines · doi:10.3390/vaccines9060678 · Cited by 22
Ikenberg, B. D., Demleitner, A. F., Thiele, T., Wiestler, B., Götze, K. S. S., Mößmer, G., & Lingor, P. (2021) · Stroke and Vascular Neurology · doi:10.1136/svn-2021-001095 · Cited by 23
Self-citationGattringer, T., Gressenberger, P., Gary, T., Wölfler, A., Kneihsl, M., & Raggam, R. B. (2021) · Stroke and Vascular Neurology · doi:10.1136/svn-2021-001142 · Cited by 23
Disentangling post-vaccination symptoms from early COVID-19
Canas, L. S., Österdahl, M. F., Deng, J., Hu, C. Y., Selvachandran, S., Polidori, L., May, A., Molteni, E., Murray, B. A. K., Chen, L., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101212 · Cited by 21
Major, A., Carll, T. C., Chan, C. W., Christenson, C., Aldarweesh, F. A., Wool, G. D., & Cohen, K. S. (2021) · Journal of Clinical Apheresis · doi:10.1002/jca.21945 · Cited by 23
Shell-mediated phagocytosis to reshape viral-vectored vaccine-induced immunity
Feng, F., Hao, H., Zhao, J., Li, Y., Zhang, Y., Li, R., Wen, Z., Wu, C., Li, M., Li, P., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121062 · Cited by 23
No Correlation between Anti-PF4 and Anti–SARS-CoV-2 Antibodies after ChAdOx1 nCoV-19 Vaccination
Uzun, G., Althaus, K., & Bakchoul, T. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2111305 · Cited by 23
D’Errico, S., Zanon, M., Concato, M., Peruch, M., Scopetti, M., Frati, P., & Fineschi, V. (2021) · Vaccines · doi:10.3390/vaccines9101116 · Cited by 24
Rodriguez, E. V. C., Bouazza, F.-Z., Dauby, N., Mullier, F., d’Otreppe, S., Tchofo, P. J., Bartiaux, M., Sirjacques, C., Roman, A., Hermans, C. R. J. R., et al. (2021) · Infection · doi:10.1007/s15010-021-01712-8 · Cited by 25
Vaccines against COVID-19: Priority to mRNA-Based Formulations
Pascolo, S. (2021) · Cells · doi:10.3390/cells10102716 · Cited by 23
Habibzadeh, F., Sajadi, M. M., Chumakov, K., Yadollahie, M., Kottilil, S., Simi, A., Stafford, K., Saeidimehr, S., Rafiei, M., & Gallo, R. C. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.35044 · Cited by 20
An overview of the ongoing challenges in SARS-CoV-2 global control
Shehata, A. A., Parvin, R., Nagy, A., Wang, Y., Azhar, T. M., Attia, Y. A., Azhar, E. I., Paul, A. K., & Rahmatullah, M. (2021) · German Journal of Microbiology · doi:10.51585/gjm.2021.2.0006 · Cited by 24
Hollstein, M. M., Münsterkötter, L., Schön, M. P., Bergmann, A., Husar, T. M., Abratis, A., Eidizadeh, A., Schaffrinski, M., Zachmann, K., Schmitz, Ä., et al. (2022) · Allergy · doi:10.1111/all.15247 · Cited by 21
Favaloro, E. J., Pasalic, L., Henry, B. M., & Lippi, G. (2022) · Pathology · doi:10.1016/j.pathol.2021.10.008 · Cited by 23
Darraj, M. A., & Al‐Mekhlafi, H. M. (2022) · Vaccines · doi:10.3390/vaccines10020223 · Cited by 24
COVID-19 and Autoimmune Liver Diseases
Floreani, A., & Martin, S. D. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11102681 · Cited by 23
Potential mechanisms of vaccine-induced thrombosis
Marietta, M., Coluccio, V., & Luppi, M. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.08.002 · Cited by 25
Simpson, C. R., Kerr, S., Katikireddi, S. V., McCowan, C., Ritchie, L. D., Pan, J., Stock, S. J., Rudan, I., Tsang, R. S. M., de Lusignan, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32264-6 · Cited by 23
Doubrovinskaia, S., Mooshage, C. M., Seliger, C., Lorenz, H., Nagel, S., Lehnert, P., Purrucker, J. C., Wildemann, B., Bendszus, M., Wick, W., et al. (2022) · European Journal of Neurology · doi:10.1111/ene.15602 · Cited by 22
Mustafa, Z. U., Bashir, S., Shahid, A., Raees, I., Salman, M., Merchant, H. A., Aldeyab, M. A., Kow, C. S., & Hasan, S. S. (2022) · Viruses · doi:10.3390/v14112344 · Cited by 171
Chary, M. A., Barbuto, A. F., Izadmehr, S., Tarsillo, M., Fleischer, E., & Burns, M. M. (2023) · Journal of Medical Toxicology · doi:10.1007/s13181-023-00931-9 · Cited by 25
Konstantinides, S. (2021) · European Respiratory Journal · doi:10.1183/13993003.01111-2021 · Cited by 23
Covid-19: Rare immune response may cause clots after AstraZeneca vaccine, say researchers
Wise, J. (2021) · BMJ · doi:10.1136/bmj.n954 · Cited by 23
COVID ‐19 vaccine hesitancy: a unique set of challenges
Danchin, M. H., & Buttery, J. P. (2021) · Internal Medicine Journal · doi:10.1111/imj.15599 · Cited by 23
VITT after ChAdOx1 nCoV-19 Vaccination
Weber, C., von Hundelshausen, P., & Siess, W. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2111026 · Cited by 23
VITT following Ad26.COV2.S vaccination presenting without radiographically demonstrable thrombosis
Kennedy, V. E., Wong, C. C., Hong, J. M., Peng, T., Brondfield, S., Reilly, L. M., Cornett, P. A., & Leavitt, A. D. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005388 · Cited by 22
Thrombosis with Thrombocytopenia Syndrome associated with viral vector COVID-19 vaccines
Cattaneo, M. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.05.031 · Cited by 22
Magro, F., Nuzzo, A., Abreu, C., Libânio, D., Rodríguez–Lago, I., Pawlak, K. M., Hollenbach, M., Brouwer, W. P., & Siau, K. (2021) · United European Gastroenterology Journal · doi:10.1002/ueg2.12115 · Cited by 21
McFadyen, J. D., Sharma, P., Moon, M. J., Noonan, J. E., Goodall, E. W., Tran, H. A., & Peter, K. (2021) · British Journal of Haematology · doi:10.1111/bjh.17750 · Cited by 22
Alghamdi, A., Alkazemi, A., Alissa, A. S., Alghamdi, I., Alwarafi, G., & Waggas, H. A. (2021) · Intervirology · doi:10.1159/000519456 · Cited by 22
Herpes zoster after COVID‐19 vaccination—Can the vaccine reactivate latent zoster virus?
Palanivel, J. A. (2021) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.14470 · Cited by 22
Uaprasert, N., Panrong, K., Rojnuckarin, P., & Chiasakul, T. (2021) · Thrombosis Journal · doi:10.1186/s12959-021-00340-4 · Cited by 22
Root-Bernstein, R. S. (2021) · BioEssays · doi:10.1002/bies.202100158 · Cited by 22
Pitkänen, H. H., Jouppila, A., Helin, T., Dulipati, V., Kotimaa, J. P., Meri, S., Kantele, A., Jalkanen, P., Julkunen, I., & Lassila, R. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.10.027 · Cited by 22
Baek, D. W., Hwang, S., Kim, J., Lee, J. M., Cho, H. J., Moon, J. H., Hwang, N., Jeong, J. Y., Lee, S.-W., & Sohn, S. K. (2021) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2021.2010801 · Cited by 22
Kheyrandish, S., Rastgar, A., Arab‐Zozani, M., & Sarab, G. A. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.794599 · Cited by 22
Waqar, U., Ahmed, S., Gardezi, S. H. A., Tahir, M. S., Abıdın, Z. U., Hussain, A. S., Ali, N. B., & Mahmood, S. F. (2021) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296211068487 · Cited by 22
Matar, R., Than, C. A., Nakanishi, H., Daniel, R. S., Smayra, K., Sim, B. L., Beran, A., & Danoun, O. A. (2022) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000001113 · Cited by 22
Acquired Hemophilia A Developed Post COVID-19 Vaccine: An Extremely Rare Complication
Soliman, D. S., Battah, A. A., Alfaridi, D., & Ibrahim, F. A. (2022) · Journal of Medical Cases · doi:10.14740/jmc3827 · Cited by 22
Metadata
- Authors
- Greinacher, A., Thiele, T., Warkentin, T. E., Weisser, K., Kyrle, P. A., & Eichinger, S.
- Affiliations
- Universitätsmedizin Greifswald (DE)
- Corresponding author
- Greinacher, Andreas
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-06-03
- Volume
- 384
- Issue
- 22
- Pages
- 2092-2101
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8095372
- OpenAlex
- W3140226555
- Cited by
- 2,259
- References
- 27
- Citations by year
- 2026: 77 · 2025: 139 · 2024: 171 · 2023: 297 · 2022: 725 · 2021: 848
- FWCI
- 479.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (Projektnummer 374031971 – TRR 240)
- Topics
- Health Sciences › Medicine › Hematology › Heparin-Induced Thrombocytopenia and Thrombosis
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- ChAdOx1 nCoV-19 vaccine, AstraZeneca COVID-19 vaccine, vaccine-associated thrombosis, platelet factor 4, PF4/heparin antibodies, platelet-activating antibodies, cerebral venous thrombosis, pulmonary embolism, splanchnic vein thrombosis, disseminated intravascular coagulation, heparin, Fc receptor blockade, gamma globulin
- MeSH terms
- COVID-19 Vaccines, ChAdOx1 nCoV-19, Adult, Autoantibodies, Autoimmune Diseases, Blood Chemical Analysis, Disseminated Intravascular Coagulation, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Middle Aged, Platelet Factor 4, Thrombocytopenia, Thrombosis, Platelet Activation, Fatal Outcome, Intracranial Hemorrhages, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
